Answers are grounded in this paper and cite their sources.
Phase 1 trial investigates ruxolitinib's effect on immune response in malaria-infected participants, suggesting potential host-directed therapy benefits.
Flow cytometry files (fcs) from Aurora, and gating files (wsp, flow jo) for PBMCs collected during controled human malaria infection studies - ACTRN12621000866808 - to test the impact of host-directed therapy ruxolitinib when co-administered with anti-malarial treatment. PBMCs were stained with indicated panel. DAY of sample collection and DUMMY number of participant is indicated in fcs file.
No takes yet. Share an insight, caveat, or question.
Bukali et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: